Taiwan Stock Exchange · Healthcare
SciVision Biotech stock from India: price, numbers and tax
SciVision Biotech (1786) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
SciVision Biotech at a glance
- Price
- NT$50.60+NT$1.50 (3.05%)
- Market cap
- NT$3.68B
- Day range
- NT$49.55 – NT$51.90
- P/E
- 26.08
- Dividend yield
- 3.77%
- Volume
- 659.89K
- 1 month
- +25.71%
- 6 months
- -9.64%
- YTD
- -30.30%
- 1 year
- -31.99%
- 5 years
- +2.22%
SciVision Biotech statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | NT$886.6M | NT$883.3M | NT$713.0M | NT$557.3M | NT$505.5M |
| Gross profit | NT$638.4M | NT$655.7M | NT$512.5M | NT$371.9M | NT$341.8M |
| Operating income | NT$189.9M | NT$248.1M | NT$199.6M | NT$176.2M | NT$124.2M |
| Net income | NT$162.3M | NT$242.3M | NT$177.9M | NT$141.7M | NT$101.7M |
| Earnings per share | NT$2.24 | NT$3.51 | NT$2.66 | NT$2.14 | NT$1.54 |
| EBITDA | NT$270.3M | NT$362.5M | NT$281.3M | NT$238.3M | NT$177.3M |
| Total assets | NT$2.7B | NT$2.4B | NT$2.2B | NT$2.1B | NT$2.3B |
| Total debt | NT$485.1M | NT$224.2M | NT$347.9M | NT$416.1M | NT$635.4M |
| Cash and short-term investments | NT$1.1B | NT$871.4M | NT$804.1M | NT$673.9M | NT$695.8M |
| Shareholders' equity | NT$2.0B | NT$1.9B | NT$1.6B | NT$1.5B | NT$1.4B |
| Operating cash flow | NT$124.0M | NT$269.9M | NT$272.0M | NT$178.2M | NT$98.5M |
| Free cash flow | NT$22.5M | NT$235.0M | NT$257.2M | NT$163.2M | NT$72.7M |
| Capital expenditure | −NT$101.5M | −NT$34.9M | −NT$14.8M | −NT$15.0M | −NT$25.8M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in TWD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Sinphar Pharmaceutical | 1734.TW | NT$30.05 | NT$6.06B |
| SCI Pharmtech | 4119.TW | NT$50.30 | NT$6.01B |
| Panion & Bf Biotech | 1760.TW | NT$47.55 | NT$4.08B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in SciVision Biotech from India
What SciVision Biotech does
SciVision Biotech Inc. develops and manufactures medical-grade hyaluronic acid products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. SciVision Biotech operates in the Medical - Instruments & Supplies industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell SciVision Biotech shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the TWD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.